Literature DB >> 12732632

Enhanced immune presentation of a single-chain major histocompatibility complex class I molecule engineered to optimize linkage of a C-terminally extended peptide.

Lonnie Lybarger1, Y Y Lawrence Yu, Michael J Miley, Daved H Fremont, Nancy Myers, Tina Primeau, Steven M Truscott, Janet M Connolly, Ted H Hansen.   

Abstract

Major histocompatibility complex class I molecules can be expressed as single polypeptides wherein the antigenic peptide, beta2-microglobulin, and heavy chain are attached by flexible linkers. These molecules, single-chain trimers (SCTs), are remarkably stable at the cell surface compared with native (noncovalently attached) class I molecules. In this study, we used a structure-based approach to engineer an F pocket variant SCT of the murine class I molecule Kb that presents the SIINFEKL epitope of ovalbumin. Mutation of heavy chain residue Tyr84 (Y84A) in the SCT resulted in enhanced serological and cytolytic CD8 T cell recognition of the covalently linked peptide due to better accommodation of the linker extending from the C terminus of the peptide. These SCTs exhibit significant cell-surface stability, which we hypothesize is rendered by their ability to continuously and efficiently rebind the covalently attached peptide. In addition, we demonstrate that SCT technology can be applied to tetramer construction using recombinant SCTs expressed in Escherichia coli. SCT-based tetramers could have applications for the enumeration of T and natural killer cells that recognize peptide.class I complexes prone to dissociation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12732632     DOI: 10.1074/jbc.M303716200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

Review 1.  Properties and applications of single-chain major histocompatibility complex class I molecules.

Authors:  Eleni Kotsiou; Joanna Brzostek; Keith G Gould
Journal:  Antioxid Redox Signal       Date:  2011-03-31       Impact factor: 8.401

2.  Single chain MHC I trimer-based DNA vaccines for protection against Listeria monocytogenes infection.

Authors:  Sojung Kim; Adam Zuiani; Javier A Carrero; Ted H Hansen
Journal:  Vaccine       Date:  2012-01-26       Impact factor: 3.641

3.  Structural engineering of pMHC reagents for T cell vaccines and diagnostics.

Authors:  Vesselin Mitaksov; Steven M Truscott; Lonnie Lybarger; Janet M Connolly; Ted H Hansen; Daved H Fremont
Journal:  Chem Biol       Date:  2007-08

4.  Human C-type lectin domain family 4, member C (CLEC4C/BDCA-2/CD303) is a receptor for asialo-galactosyl-oligosaccharides.

Authors:  Elena Riboldi; Roberta Daniele; Carmen Parola; Antonio Inforzato; Phoebe L Arnold; Daniela Bosisio; Daved H Fremont; Antonio Bastone; Marco Colonna; Silvano Sozzani
Journal:  J Biol Chem       Date:  2011-08-31       Impact factor: 5.157

5.  Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope.

Authors:  C-H Huang; S Peng; L He; Y-C Tsai; D A K Boyd; T H Hansen; T-C Wu; C-F Hung
Journal:  Gene Ther       Date:  2005-08       Impact factor: 5.250

6.  Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens.

Authors:  Lijin Li; John M Herndon; Steven M Truscott; Ted H Hansen; Timothy P Fleming; Peter Goedegebuure; William E Gillanders
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

Review 7.  Basic and translational applications of engineered MHC class I proteins.

Authors:  Ted H Hansen; Janet M Connolly; Keith G Gould; Daved H Fremont
Journal:  Trends Immunol       Date:  2010-09-09       Impact factor: 16.687

Review 8.  Applications of major histocompatibility complex class I molecules expressed as single chains.

Authors:  Tina Primeau; Nancy B Myers; Y Y Lawrence Yu; Lonnie Lybarger; Xiaoli Wang; Steven M Truscott; Ted H Hansen; Janet M Connolly
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

9.  Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.

Authors:  Ben C King; Angela D Hamblin; Philip M Savage; Leon R Douglas; Ted H Hansen; Ruth R French; Peter W M Johnson; Martin J Glennie
Journal:  Cancer Immunol Immunother       Date:  2013-04-19       Impact factor: 6.968

10.  Human major histocompatibility complex (MHC) class I molecules with disulfide traps secure disease-related antigenic peptides and exclude competitor peptides.

Authors:  Steven M Truscott; Xiaoli Wang; Lonnie Lybarger; William E Biddison; Cortez McBerry; John M Martinko; Janet M Connolly; Gerald P Linette; Daved H Fremont; Ted H Hansen; Beatriz M Carreno
Journal:  J Biol Chem       Date:  2008-01-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.